A phase II study of the cell cycle checkpoint kinases 1 and 2 inhibitor (LY2606368; Prexasertib monomesylate monohydrate) in sporadic high-grade serous ovarian cancer (HGSOC) and germline BRCA mutation-associated ovarian cancer (gBRCAm+ OvCa)

Published 2016 View Full Article

Authors

Keywords

Journal

ANNALS OF ONCOLOGY

Volume 27, Issue suppl_6, Pages -

Publisher

Oxford University Press (OUP)

Online

2017-02-04

DOI

10.1093/annonc/mdw374.02

Ask authors/readers for more resources

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

ANNALS OF ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Find the ideal target journal for your manuscript

Become a Peeref-certified reviewer